825 related articles for article (PubMed ID: 11485624)
21. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
Nabatov AA; Pollakis G; Linnemann T; Kliphius A; Chalaby MI; Paxton WA
J Virol; 2004 Jan; 78(1):524-30. PubMed ID: 14671134
[TBL] [Abstract][Full Text] [Related]
22. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
Labrosse B; Treboute C; Brelot A; Alizon M
J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
[TBL] [Abstract][Full Text] [Related]
23. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
24. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
25. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
26. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
[TBL] [Abstract][Full Text] [Related]
27. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.
Li Y; Rey-Cuille MA; Hu SL
AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1473-9. PubMed ID: 11709091
[TBL] [Abstract][Full Text] [Related]
28. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop.
Hansen JE; Jansson B; Gram GJ; Clausen H; Nielsen JO; Olofsson S
Arch Virol; 1996; 141(2):291-300. PubMed ID: 8634021
[TBL] [Abstract][Full Text] [Related]
30. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
31. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
32. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
33. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
34. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.
Takizawa M; Miyauchi K; Urano E; Kusagawa S; Kitamura K; Naganawa S; Murakami T; Honda M; Yamamoto N; Komano J
AIDS; 2011 Nov; 25(18):2209-16. PubMed ID: 21866041
[TBL] [Abstract][Full Text] [Related]
35. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
[TBL] [Abstract][Full Text] [Related]
36. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
Edwards TG; Hoffman TL; Baribaud F; Wyss S; LaBranche CC; Romano J; Adkinson J; Sharron M; Hoxie JA; Doms RW
J Virol; 2001 Jun; 75(11):5230-9. PubMed ID: 11333905
[TBL] [Abstract][Full Text] [Related]
37. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
Platt EJ; Shea DM; Rose PP; Kabat D
J Virol; 2005 Apr; 79(7):4357-68. PubMed ID: 15767436
[TBL] [Abstract][Full Text] [Related]
38. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
Pollakis G; Kang S; Kliphuis A; Chalaby MI; Goudsmit J; Paxton WA
J Biol Chem; 2001 Apr; 276(16):13433-41. PubMed ID: 11278567
[TBL] [Abstract][Full Text] [Related]
39. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
40. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
